05:14 PM EDT, 07/08/2024 (MT Newswires) -- Kymera Therapeutics ( KYMR ) said Monday Sanofi (SNY) has informed the company over its plan to expand the ongoing Hidradenitis Suppurativa and Atopic Dermatitis mid-stage trials to more rapidly progress towards pivotal studies.

Kymera said the expansion followed a review of preliminary KT-474 data by an Independent Data Review Committee.

"This expansion, supported by the results of the interim analysis, is intended to accelerate overall timelines and inform future registrational trials," said CEO Nello Mainolfi.

Kymera shares were rising past 11% in after-hours trading.

Price: 35.70, Change: +3.74, Percent Change: +11.70